SCHEMBL23576327

SCHEMBL23576327

CCOc1ccc(-c2ccc(-c3cc(C(=O)O)c4cc(F)ccc4n3)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 8/20 0.71
▸ KDM4E B2RXH2 4/20 0.71
▸ ALDH1A1 P00352 4/20 0.71
▸ SMN1; SMN2 Q16637 3/20 0.71
▸ HPGD P15428 3/20 0.71
▸ NPC1 O15118 2/20 0.71
▸ RAB9A P51151 2/20 0.71
▸ LMNA P02545 1/20 0.71
▸ PLA2G2A P14555 1/20 0.65
▸ HSD17B10 Q99714 4/20 0.63
▸ MEN1 O00255 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ GAA P10253 1/20 0.62
▸ PDE10A Q9Y233 1/20 0.58
▸ CYP1A2 P05177 2/20 0.56
▸ TSHR P16473 1/20 0.56
▸ EIF4A1 P60842 1/20 0.53
▸ HIF1A Q16665 2/20 0.53
▸ PTGES O14684 1/20 0.53
▸ ALOX5 P09917 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29617652 1.00 DHODH (0.71) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23578618 0.94 DHODH (0.67) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL29958903 0.94 DHODH (0.67) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL29958851 0.91 DHODH (0.62) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23590331 0.91 DHODH (0.62) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL29959049 0.91 DHODH (0.59) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23579019 0.91 DHODH (0.62) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23590272 0.91 DHODH (0.62) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23578600 0.91 DHODH (0.59) DHODHKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL23590068 0.91 DHODH (0.74) DHODHKDM4EALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240325373-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2024-10-03 — — US disclosed
EP-4438042-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE Ohio State Innovation Foundation (US) 2024-10-02 — — EP disclosed
US-20240294477-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-09-05 — — US disclosed
EP-3793562-B1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-06-19 — — EP disclosed
US-11999697-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase OHIO STATE INNOVATION FOUNDATION (US) 2024-06-04 — — US disclosed
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed
US-20230109418-A1 COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2023-04-06 — — US disclosed
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase OHIO STATE INNOVATION FOUNDATION (US) 2022-04-26 — — US disclosed
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE HENDRIX COLLEGE 2022-03-03 — — US disclosed
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE HENDRIX COLLEGE 2022-03-03 — — US disclosed
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION 2021-08-19 — — US disclosed
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION 2021-08-19 — — US disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed
WO-2021134045-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed
WO-2021133833-A1 COMPOSITIONS FOR USE IN THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed
WO-2021133831-A1 COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed
WO-2021134042-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240325373-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT DHODH, CD47, IDH1 DHODH 1/4885KDM4E 415/4885ALDH1A1 217/4885
US-11312686-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase DHODH, DLD, DPYD DHODH 1/4885KDM4E 474/4885ALDH1A1 72/4885
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD DHODH 1/4885KDM4E 1396/4885ALDH1A1 88/4885
US-20230109418-A1 COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DDO, DLD DHODH 1/4885KDM4E 992/4885ALDH1A1 120/4885
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, FAH DHODH 1/4885KDM4E 580/4885ALDH1A1 56/4885
US-20240294477-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885KDM4E 523/4885ALDH1A1 64/4885
US-20220064119-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885KDM4E 523/4885ALDH1A1 64/4885
US-20210253531-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, DPYD DHODH 1/4885KDM4E 474/4885ALDH1A1 72/4885
US-11999697-B2 Methods and compositions for inhibition of dihydroorotate dehydrogenase DHODH, DLD, DPYD DHODH 1/4885KDM4E 523/4885ALDH1A1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback